AUS
NZ
UK
CA
USA
IND
Highlights
- Lantheus, a leading radiopharmaceutical company, acquired a 12.16% stake in Radiopharm Theranostics (ASX:RAD) through an $8 million placement.
- The placement price of 6 cents per share represents a 150% premium to Radiopharm's last closing price of 2.4 cents.
- The funding will support the clinical development of Radiopharm’s pipeline, including its Lu-RAD202 product for breast and gastric cancers.
Radiopharm Theranostics (ASX:RAD) has secured a significant boost to its operations with an $8 million placement to Lantheus, a Massachusetts-based radiopharmaceutical-focused company with a global presence, including offices in Sweden and Canada. This transaction grants Lantheus a 12.16% stake in Radiopharm, further strengthening collaboration between the two entities.
The placement price of 6 cents per share reflects a 150% premium to Radiopharm's last closing price of 2.4 cents. Following the announcement, Radiopharm's shares surged 40% to 3.4 cents per share, highlighting the market's response to the deal, though the increase is attributed partly to the company’s low liquidity and $52 million market capitalization.
Clinical Development Focus
The proceeds from this placement are expected to bolster Radiopharm's existing clinical pipeline, particularly the development of its Lu-RAD202 product. Lu-RAD202 is designed to target breast and gastric cancer patients by detecting the chemical signals secreted by these tumors. This innovative approach may enable the development of co-treatment solutions for multiple cancer types.
The company recently received approval to commence human safety studies for Lu-RAD202, marking a significant milestone in its journey toward producing effective therapies. Beyond cancer treatment, Radiopharm also engages in the clinical imaging sector, further diversifying its operational scope.
Building on Established Collaboration
Radiopharm CEO Riccardo Canevari expressed satisfaction with the ongoing collaboration between the two companies, emphasizing the shared vision driving this partnership. The initial investment, announced in June 2024, laid the groundwork for this latest development, underscoring the strategic alignment of both companies in advancing radiopharmaceutical technologies.
This deal not only positions Radiopharm for sustained growth but also demonstrates Lantheus’ commitment to supporting innovative healthcare solutions globally. Radiopharm’s focus on targeting multiple tumor types and expanding its imaging capabilities underscores its ambition to address unmet needs in oncology.
Radiopharm Theranostics continues to gain traction in the radiopharmaceutical space, with the Lantheus investment marking another critical step in its evolution. As the collaboration deepens, both companies are poised to unlock opportunities that leverage their combined expertise, aiming to make strides in cancer treatment and diagnostic imaging.
